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Abstract
MHC class Ia-restricted CD8+ T cells are important mediators of the adaptive immune response against infections caused by
intracellular microorganisms. Whereas antigen-specific effector CD8+ T cells can clear infection caused by intracellular
pathogens, in some circumstances, the immune response is suboptimal and the microorganisms survive, causing host death
or chronic infection. Here, we explored the cellular and molecular mechanisms that could explain why CD8+ T cell-mediated
immunity during infection with the human protozoan parasite Trypanosoma cruzi is not optimal. For that purpose, we
compared the CD8+ T-cell mediated immune responses in mice infected with T. cruzi or vaccinated with a recombinant
adenovirus expressing an immunodominant parasite antigen. Several functional and phenotypic characteristics of specific
CD8+ T cells overlapped. Among few exceptions was an accelerated expansion of the immune response in adenoviral
vaccinated mice when compared to infected ones. Also, there was an upregulated expression of the apoptotic-signaling
receptor CD95 on the surface of specific T cells from infected mice, which was not observed in the case of adenoviral-
vaccinated mice. Most importantly, adenoviral vaccine provided at the time of infection significantly reduced the
upregulation of CD95 expression and the proapoptotic phenotype of pathogen-specific CD8+ cells expanded during
infection. In parallel, infected adenovirus-vaccinated mice had a stronger CD8 T-cell mediated immune response and
survived an otherwise lethal infection. We concluded that a suboptimal CD8+ T-cell response is associated with an
upregulation of CD95 expression and a proapoptotic phenotype. Both can be blocked by adenoviral vaccination.
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Introduction
The digenetic intracellular protozoan parasite Trypanosoma cruzi
(T. cruzi) is the etiologic agent of Chagas’ disease, an acute and
chronic illness affecting millions of individual in the Americas [1].
After contact with T. cruzi, humans and mice develop MHC class
Ia-restricted CD8+ T cells specific for immunodominant parasite
epitopes [2–7]. In highly susceptible hosts, such as A/Sn mice, the
immune response is unable to control acute-phase pathology and
prevent death. In most hosts, however, these specific CD8+ T cells
are critical for survival following infection, even when limited
numbers of parasites initiate infection [2,8]. Despite the CD8+ T
cell-mediated immune response, T. cruzi usually survives and
establishes a life-long chronic infection. Parasite persistence is an
important element of chronic-phase pathologies that occur many
years or even decades after initial infection [9–15]. Therefore, in
any circumstance, the CD8+ T cell-mediated immune response
completely eliminate the parasite. The reason for this ineffective or
suboptimal immune response is not fully understood. Several
potentially significant mechanisms have been described for
parasite evasion of the immune response and may account for
short- and long-term parasite survival [16].
In contrast to the observations made during experimental
mouse infection, immunization with adenoviral vaccines express-
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ing a parasite immunodominant antigen can elicit a strong CD8+
T cell-mediated immunity against acute and late pathologies after
an infectious challenge with T. cruzi [17–21]. Although it is well
established that these specific CD8+ T cells induced by vaccination
eliminate parasites, it is not clear which properties of these T cells
are responsible for sustaining highly effective immunity against T.
cruzi-induced pathology. It is paradoxical that specific CD8+ T
cells elicited by infection or vaccination are cytotoxic in vivo and
secrete IFN-c, which are mechanisms that mediate protective
immunity against T. cruzi [5,17].
To understand this problem, we hypothesized that CD8+ T cells
induced during infection had different functional or phenotypic
properties from specific T cells generated by adenoviral vaccines.
Accordingly, our approach consisted of a detailed comparison of
the kinetics, function, and phenotype of the CD8+ T cells induced
by either experimental infection or immunization with recombi-
nant adenoviral vaccine expressing the immunodominant antigen,
amastigote surface protein 2, of T. cruzi (AdASP-2). Essentially, our
results showed that parasite infection and AdASP-2 vaccination
elicited effector CD8+ T cells that mostly overlapped in phenotype
and function. An important and recurrent exception was the
overexpression of the apoptotic receptor CD95 on the surface of
the specific CD8+ T cells observed during T. cruzi infection. In
contrast, AdASP-2 vaccine induced T cells that failed to
upregulate CD95 expression. Moreover, immunization with the
AdASP-2 vaccine performed simultaneously with the infectious
challenge pre-programs specific CD8+ T cells to mediate
protective immunity. In adenoviral-vaccinated animals, protective
CD8+ T cells that expand after an infectious challenge had
reduced CD95 expression and a reduced proapoptotic phenotype.
Our observation indicates that CD95 expression by suboptimal
CD8+ T cells during infection may be one of the key factors
leading to an early increase in apoptosis and a reduced immune
response. Furthermore, adenoviral vaccines may pre-program
pathogen-specific T cells by reducing the levels of CD95
expression and apoptosis and, therefore, promote T cell accumu-
lation and efficacy.
Results
Protective CD8+ T cells are elicited by a single dose of
AdASP-2 vaccine provided shortly before or at the same
time as an infectious challenge
Recently, the AdASP-2 vaccine was described [17–21]. This
vaccine expresses the immunodominant antigen ASP-2, a member
of the trans-sialidase superfamily of surface proteins of T. cruzi. This
antigen is abundantly expressed by intracellular amastigotes and
contains 2 immunodominant epitopes (one for H-2Kk [TE-
WETGQI] and one for H-2Kb [VNHRFTLV]) recognized by
protective CD8+ T cells during mouse infection with the Y strain
of T. cruzi. (Figure 1A and B, [ref. 3,5]).
To establish a simple method to study the induction of
protective CD8+ T cells against T. cruzi infection, we immunized
Figure 1. Schematic representation of the ASP-2 antigen and
its expression in intra-cellular amastigotes of T. cruzi. A) The
protein is a prototypical member of the trans-sialidase family of T. cruzi
surface antigens containing a putative signal peptide at the N-terminal
region, 2 ASP-box sequences, and a VTV-box at the C-terminal domain.
The protein is attached to the membrane through a glycopho-
sphatidylinositol anchor. B) ASP-2 expression in intra-cellular amasti-
gotes was determined by immunofluorescence with the specific MAb
K22. HeLa cells were infected for 48 h with trypomastigotes of the Y
strain. After fixation, indirect immunofluorescence and DAPI staining
were performed and imaged under fluorescence microscopy. Bar,
14 mM. Photomicrography kindly provided by Dr. Clara Claser (Singa-
pore Immunology Network -SIgN, Singapore).
doi:10.1371/journal.ppat.1002699.g001
Author Summary
Killer lymphocytes are important mediators of the immu-
nological resistance against infections caused by virus,
bacteria and parasites. In some circumstances, however,
these lymphocytes are unable to properly eliminate the
microorganisms which survive, causing death or establish-
ing chronic infections. The purpose of our study was to
understand why these killer cells do not succeed during
infection with a human protozoan parasite. For that
purpose, we compared the immune responses in animals
infected or vaccinated. Many characteristics of these killer
cells were similar. Among few exceptions was an acceler-
ated immune response in vaccinated animals when
compared to infected ones. Also, we observed on the
surface of the killer lymphocytes from infected, but not
from vaccinated animals, an increased expression of a
protein involved in signaling cell death. Most importantly,
vaccine significantly reduced the higher expression of this
cell-death receptor. In parallel, these animals had a
stronger immune response and cured infection. We
concluded that a deficient killer cell response observed
during infection was associated with an upregulation of
this cell-death receptor and it was changed by vaccination.
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susceptible A/Sn mice with a single dose of AdASP-2 vaccine. As
shown in Figure 2A, i.m. immunization with increasing doses of
AdASP-2 (ranging from 106 to 108 pfu) 7 days prior to infection
led to a dose-dependent reduction in peak parasitemia. Vaccina-
tion also significantly retarded or reduced mouse mortality
(Figure 2B). As a control, mice injected with the higher dose of
adenovirus vector expressing the b-galactosidase protein (Adb-gal)
developed higher parasitemia (Figure 2A) and died sooner than the
other mouse groups following experimental challenge (Figure 2B).
From the experiment described above, we considered a single
dose of $108 pfu sufficient to protect against a challenge with T.
cruzi. The timing of administration of the adenoviral vaccine was
determined by immunizations performed from 7 days before up to
7 days after infection. As shown in Figure 2C and 2D, even when
administered on the same day as the infectious challenge,
immunization with AdASP-2 vaccine elicited significant protective
immunity, impairing the development of parasitemia and
improving mouse survival. In contrast, administration of
AdASP-2 vaccine after the challenge had limited or no impact
on infection.
To determine whether the route of immunization affected
protective immunity, we injected AdASP-2 vaccine on the same
day as infection by the i.m., s.c., or i.p routes. While mice
immunized i.m. or s.c. controlled parasitemia and survived
Figure 2. Parasitemia and mortality in A/Sn mice immunized with AdASP-2 vaccine and challenged with trypomastigotes. A) A/Sn
mice were immunized i.m. with the indicated doses (pfu) of AdASP-2 vaccine or control Adb-gal. Seven days later, mice were challenged s.c. with 150
bloodstream trypomastigotes of the Y strain of T. cruzi. Parasitemia was followed daily from days 9 to 13 after challenge. The results represent the
mean 6 SD values for 6 mice. At the peak parasitemia (day 11), values of mice immunized with each different dose were compared by one-way
ANOVA and Tukey HSD tests and the results were as follows: i) Groups of mice that received doses of 108 or 107 pfu of AdASP-2 vaccine had values
lower than the group of mice injected with Adb-gal (P,0.01). B) Kaplan–Meier curves for survival of the different groups were compared using the
logrank test. The results of the comparisons were as follows: i) Groups of mice injected with 108 or 107 pfu of AdASP-2 vaccine survived longer than
the group injected with Adb-gal (P,0.01). C) A/Sn mice were immunized i.m. on the indicated days before or after infection with AdASP-2 vaccine or
control Adb-gal (26108 pfu/mouse). All mice were challenged s.c. as described above. Although the day of the peak parasitemia was different for
each group, we used the maximal values for statistical comparison. The results of the comparisons were as follows: i) Mice vaccinated on day27 (red)
with AdASP-2 vaccine had values lower than those of any other group. ii) Mice vaccinated on days 0 (green) or +4 (yellow) with AdASP-2 vaccine had
values lower than the group of mice injected with Adb-gal (black) or AdASP-2 on day +7 (blue, P,0.01). D) Kaplan–Meier curves for survival of the
different groups were compared and the results were as follows: i) Groups of mice vaccinated with AdASP-2 vaccine on days 27 (red) or 0 (green)
survived longer than the groups of mice injected with Adb-gal (black) or AdASP-2 vaccine on days +4 (yellow) or +7 (blue) (P,0.01 in all cases). E) A/
Sn mice were immunized with AdASP-2 vaccine or Adb-gal (26108 pfu/mouse) by the indicated routes (i.m., s.c., or i.p.). All mice were challenged s.c.
on the same day as the immunization, as described above. The parasitemia data for each mouse group are represented in terms of mean6 SD (n = 6).
Although the day of the peak parasitemia was different for each group, we used the maximal values for statistical comparison. The results of the
comparisons were that mice vaccinated i.m. or s.c. with the AdASP-2 vaccine had values lower than those of any other groups (P,0.01). F) Kaplan–
Meier curves for survival of the different groups were compared and the results were as follows: i) Mice vaccinated i.m. or s.c. with the AdASP-2
vaccine survived longer than any other groups (P,0.01). ii) Mice vaccinated i.p. with AdASP-2 vaccine survived longer than mice that received Adb-
gal (P,0.05). G) A/Sn mice were immunized i.m. with AdASP-2 vaccine or control Adb-gal (26108 pfu/mouse). Seven days later, mice were
challenged s.c. as described above. Before and after challenge, mice were treated as described in the Methods section with rat IgG (control) or anti-
CD8 MAb. The parasitemia for each mouse group is represented as mean 6 SD (n = 6). Although the day of the peak parasitemia was different for
each group, we used the maximal values for statistical comparison. AdASP-2-immunized mice treated with rat IgG had a significantly lower
parasitemia (P,0.01) when compared to those of non-immune animals or AdASP-2-vaccinated mice treated with anti-CD8 MAb. H) Kaplan–Meier
curves for survival of the different groups were compared and the results showed that AdASP-2-immunized mice treated with rat IgG survived
significantly longer (P,0.01) than non-immune animals or AdASP-2-immunized mice treated with anti-CD8 MAb. The results described above are
representative of 2 or more independent experiments.
doi:10.1371/journal.ppat.1002699.g002
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infection, animals injected by the i.p. route showed limited control
of parasite development and mouse survival (Figure 2E and 2F).
Finally, to evaluate the role of CD8+ T cells for protection,
AdASP-2-immunized mice were treated with MAb to CD8 prior
to infection. The depletion of CD8+ T cells led to a complete
reversal of immunity as evaluated by parasitemia (Figure 2G) and
mouse survival (Figure 2H). We concluded that a single dose of
26108 pfu of AdASP-2 vaccine administered 7 days prior to or
even on the same day as the infectious challenge can be used as a
simple model to elicit protective CD8+ T cells against an otherwise
lethal infection with T. cruzi.
To determine whether AdASP-2 vaccination cured T. cruzi
infection, we collected 0.5 mL of the blood 24 months after
challenge and transferred i.p. to naı¨ve A/Sn mice. Four of the 15
mice (26.66%) developed patent parasitemia and died. In contrast,
100% of control mice injected with 150 parasites developed patent
parasitemia and died (data not shown). Based on that, we
considered that AdASP-2 vaccination in fact cured T. cruzi
infection in 73.33% of the vaccinated animals. The absence of
infection can not be attributed to passively transferred immunity
because injection of 0.5 mL of blood of vaccinated mice admixed
with 100 viable bloodstream trypomastigotes also does not confer
protection to naı¨ve A/Sn (data not shown).
Higher numbers of multifunctional specific CD8+ T
lymphocytes are present as a result of the adenovirus
vaccination
The fact that AdASP-2 vaccine administered simultaneously
with the infectious challenge could provide a significant degree of
protective immunity raised the possibility that vaccine- or T. cruzi-
induced CD8+ T cells had different traits. To understand the
cellular basis for the biological properties of the CD8+ T cells
elicited by infection or vaccination, we compared certain
functional and phenotypic profiles.
Groups of A/Sn mice were immunized according to the
protocol described in Figure 3A. In these experiments, vaccination
and challenge were performed simultaneously to avoid any
obvious boosting effect that might interfere with interpretation of
the results. Our analysis of the immune response was done on day
19 post infection just prior to the Adb-gal-immunized control mice
started to die. We observed consistently similar frequencies of
peptide-specific cells in mice that were infected with T. cruzi or
vaccinated with AdASP2 (Figure 3B). Most important was the fact
that significantly more peptide-specific cells were detected in
infected AdASP-2- vaccinated mice. The frequency of specific
CD8+ T cells, as determined by staining with the multimer H2Kk-
TEWETGQI, was approximately 4 times higher in infected
AdASP-2-immunized mice than in mice that had only been
immunized or infected (Figure 3B).
To compare important functional aspects of antigen-specific
CD8+ T cells, we performed staining of CD8+ T cells following in
vitro peptide stimulation for surface mobilization of CD107a [22], a
marker for T-cell degranulation, and intracellular effector
cytokines (IFN-c and TNF-a, intra-cellular cytokine staining-
ICS). Estimates of frequencies of splenic functional peptide-specific
CD8+ cells that mobilize CD107a to their surfaces, express IFN-c
or TNF-a were 6- to 9-fold higher in infected AdASP-2-
immunized mice than in the spleen of mice that had been only
immunized or infected (Figure 3C). Spleen cells stimulated with
the peptide TEWETGQI revealed a large fraction of multifunc-
tional CD8+ cells in both, infected or immunized mice (Gr.2 and
Gr. 3, Figure 3D and 3E). The analysis of the frequency of CD8+
T cells expressing different combinations of the effector molecules
in mice infected with T. cruzi or immunized with AdASP-2 vaccine
revealed that multifunctional triple-positive cells was the largest
population in both cases, accounting for 57.36% or 47.25 % of the
peptide-specific cells in infected or immunized mice, respectively.
Among the double-positive cells, we found 14.15 % or 12.90 % of
IFN-c+/TNF-a+ cells in infected or vaccinated mice, respectively.
The difference in terms of frequency was the higher proportion of
CD107a+/TNF-a+ or CD107a+/IFN-c+ double-positive CD8+ T
cells in splenic cells from infected mice or immunized mice,
respectively. We considered that the quality of the specific CD8+ T
cells elicited by T. cruzi infection or AdASP-2 immunization
generally overlapped.
The pattern of effector molecules expressed by specific CD8+
cells in infected AdASP-2-immunized mice retained a high
frequency of triple-positive (28.28 %) and double-positive IFN-
c+/TNF-a+ cells (47.25 %) The difference we observed in this case
was significantly higher frequencies of single-positive TNF-a+ cells
in splenic cells of infected AdASP-2-immunized mice when
compared to those of vaccinated or infected mice (Figure 3D
and 3E).
To confirm our analyses of the immune response, we used also
the C57BL/6 mouse model for experiments. Infected C57BL/6
mice do not succumb to acute infection and display a strong CD8+
T-cell immune response to the immunodominant epitope
VNHRFTLV [2–4,17,19,20]. After s.c. infection with 104
parasites of T. cruzi, peak parasitemia occurred on day 8 or 9
post infection (Figure S1 A). We then followed the kinetics of the
CD8 epitope-specific cells by 2 distinct assays, i.e., in vivo
cytotoxicity and ex vivo surface mobilization of CD107a and ICS
for IFN-c and TNF-a, after s.c. parasite infection or i.m.
immunization with AdASP-2 vaccine. We observed a more rapid
in vivo cytotoxic response in mice immunized with the AdASP-2
vaccine when compared to the response of the infected ones (day
8, Figure S1 B). Nevertheless, by day 12 both groups had reached
maximal levels. In infected mice, high levels of in vivo cytotoxicity
were still detected by day 30. This high in vivo cytotoxicity is
maintained for a long period of .90 days due to unknown reasons
(3). Likewise, the number of CD8+ splenocytes that mobilize
CD107a to their surfaces and express IFN-c and/or TNF-a also
appeared faster in mice immunized with the AdASP-2 vaccine
than in infected mice (day 7, Figure S1 C). However, the immune
response in vaccinated mice declined significantly at day 28 when
compared to infected mice.
Splenic cells were collected from animals that had been infected
or immunized and re-estimulated in vitro with the petptide
VNHRFTLV. At day 7, multi-functional double positive
CD107a+/IFN-c+ and triple-positive peptide-specific CD8+ cells
accounted for the largest populations of peptide-specific cells from
immunized mice (Figure S1 D). At day 15, the multifunctional
triple-positive cells accounted for the largest population in infected
or AdASP-2 immunized mice (Figure S1 E). Among the double-
positive cells, we found higher frequencies of IFN-c+/TNF-a or
CD107a+/IFN-c+ cells in infected or vaccinated mice, respective-
ly. A difference in terms of frequency was also observed by the
higher proportion of CD107a single-positive CD8+ T cells in
splenic cells from immunized mice (Figure S1 E).
At day 28, the frequencies of the distinct sub-populations
changed little in infected mice compared to day 15. In the case of
AdASP-2 immunized mice CD107a+/IFN-c+ cells accounted for
the largest population with the decline of multifunctional triple-
positive cells (Figure S1 F). An increase was also seen by the higher
proportion of CD107a single-positive CD8+ T cells in splenic cells
from immunized mice.
In addition, we compared the frequencies of specific T cells in
groups of mice that have been immunized and challenged
Suboptimal Specific CD8+ T Cells during Infection
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according to the protocol described in Figure S2 A. On day 21,
there was an increase in the frequency of peptide-specific CD8+ T
cells from infected AdASP-2-immunized mice (Gr.4) according to
the expression of effector molecules (Figure S2 B). Despite these
numerical differences, the composition of the distinct T-cell
subpopulation expressing one or more of these molecules was not
dramatically different between infected (Gr. 2) and infected
AdASP-2-immunized mice (Gr. 4, Figure S2 C and S2D). The
multifunctional T cells that expressed 2 or more effector molecules
accounted for more than 66% of the cells. However, differences
between Gr. 2 and Gr. 4 can be seen when single-positive T cells
are compared (Figure S2 C and S2 D). As we observed earlier in
Figure S1 F, there was a tendency for the accumulation of more
differentiated T cells (triple-positive) in infected mice (Gr. 2).
Further, the distribution was more heterogeneous in the cells from
AdASP-2-vaccinated mice (Gr. 3 and Gr. 4) than in the cells from
infected mice (Gr. 2).
Together with the results obtained from A/Sn mice, we
considered that the size and quality of the specific CD8+ T cells
elicited by T. cruzi infection and AdASP-2 immunization were not
dramatically different. The magnitude was similar and in terms of
effector molecules, they generally overlapped at the peak of the
Figure 3. Specific CD8+ T cell-mediated immune responses of infected, immunized or infected AdASP-2 immunized A/Sn mice. A) A/
Sn mice were immunized i.m. with Adb-gal or AdASP-2 vaccine (26108 pfu/mouse). On the same day, half of the mice were challenged s.c. with
trypomastigotes of the Y strain of T. cruzi (150 bloodstream parasites/mouse). B) Nineteen days after the immunization/challenge, we estimated the
frequency of splenic H2Kk-TEWETGQI+ CD8+ cells. The results are presented in terms of each mouse (dots) and medians (bars). C) Splenic cells were
cultured in the presence of anti-CD107a and anti-CD28, with or without the peptide TEWETGQI. After 12 h, cells were stained for CD8, IFN-c, and TNF-
a. Frequencies were initially estimated for any CD8+ that expressed surface CD107a, IFN-c or TNF-a after stimulation in vitro with peptide TEWETGQI.
D) Subsequently, we estimated the subpopulations of CD8+ cells expressing each individual molecule or combination (surface CD107a, IFN-c or TNF-
a). The results are presented as the mean6 SD frequencies of CD8+ cells for 4 mice. The asterisks and crosses denote significantly higher numbers of
peptide-specific cells than in the group of mice immunized with Adb-gal or all other groups, respectively (P,0.05). E) Pie charts show the fraction of
peptide-specific cells expressing the indicated molecules. The results are expressed as the mean values for 4 mice per group. The results are
representative of 2 independent experiments.
doi:10.1371/journal.ppat.1002699.g003
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immune response. Noteworthy were the observations that in
AdASP-2 immunized mice the immune response was faster and in
infected AdASP-2-immunized mice there was a significant
increase in the frequency of specific CD8+ T cells.
A relevant question raised from these experiments was the
possibility that the increase in the frequency of specific CD8+ T
cells was due to a bystander activation caused by the AdASP-2
vaccine. To evaluate this possibility, we determined whether the
frequency of CD8+ T cells specific for a sub-dominant epitope of
T. cruzi was also increased in infected AdASP-2-immunized mice.
For that purpose, we estimated the immune response of H-2Kb-
restricted CD8+ cells specific for the epitope TsKb-20. We found
that AdASP-2 immunization prior to infection (Gr. 4) generated a
significant increase in the frequencies of VNHRFTLV specific
CD8+ cells as estimated by the multimer staining or by expression
of IFN-c and/or TNF-a (Figure S3 B and C, respectively). In
contrast, AdASP-2 immunization prior to infection did not cause
an increase in the frequency of TsKb-20 specific CD8+ cells when
compared to mice that had been immunized with control Adb-gal
and infected with T. cruzi (Gr.2, Figure S3 C). In fact, the
frequencies of TsKb-20 specific CD8+ cells were lower. This
observation provided a strong argument against any bystander
effect of the AdASP-2 immunization.
Prevention of up-regulation of CD95 expression on
specific CD8+ T cells from mice primed with the
adenovirus based vaccine and simultaneously challenged
with blood stream trypomastigotes
Based on the fact that the magnitude and quality of the immune
response was similar in infected or immunized mice, we pursued a
further characterization of the phenotype of these specific cells that
could account for a higher frequency of specific CD8+ T cells in
infected AdASP-2-immunized mice. Splenic cells were stained for
CD8, the H2Kk-TEWETGQI multimer, and various T-cell
surface markers. Cells were collected from animals infected,
immunized, or infected-AdASP-2 immunized as described in
Figure 3A. We found a similar pattern of expression for many
molecules analyzed when we compared infected (Gr. 2) or AdASP-
2-immunized (Gr. 3) mice. Specific CD8+ T cells upregulated the
expression of CD11a, CD44, PD-1 and KLRG-1. On the other
hand, they downregulated the expression of CD62L and CD127.
Several molecules, such as CD95L, CCR7, and CTLA-4, had
unchanged expression patterns when compared to those of naive
CD8+ T cells (Figure 4).
Some molecules were expressed differently by antigen-specific
CD8+ T cells from infected or immunized mice. CD11c, CD25,
CD43 (1B11), CD69 and CD122 were expressed only on a subset
of specific CD8+ T cells of infected mice but not on CD8+ T cells
from immunized mice. CD27, BTLA and b7 expression were
down regulated only on a subset of specific CD8+ T cells of
immunized mice but not on CD8+ T cells from infected mice. To
our surprise, we consistently found that the apoptotic receptor
CD95 (Fas) was upregulated only on the surface of specific CD8+
T cells from infected but not immunized mice.
When we analyzed the phenotype of the specific CD8+ T cells of
infected AdASP-2-immunized mice (Gr. 4), we found that they
matched the ones observed on the specific CD8+ T cells from
AdASP-2 immunized mice (Gr. 3). This observation suggests that
vaccination has a dramatic influence on the phenotype of the cells
expanded after the infectious challenge.
To confirm these results, we analyzed the phenotype of splenic
CD8+ cells from immunized or infected C57BL/6 mice. Splenic
cells were collected from animals that had been infected or
immunized 28 or 14 days earlier, respectively, and stained for
CD8, the H2Kb-VNHRFTLV multimer and various T-cell
surface markers. These days were selected because they repre-
sented the peak of their immune response (Figure S1). Overall, we
found a very similar pattern of expression for most molecules
analyzed. Specific CD8+ T cells upregulated the expression of
CD11a, CD43, CD44, CD49d, CD95L, and KLRG-1. On the
other hand, they downregulated the expression of CD27, CD62L,
CD127, and BTLA. Several molecules, such as CD25, CD69,
CCR7, and CTLA-4, had unchanged expression patterns when
compared to those of naive CD8+ T cells (Figure S4 A).
Only a few molecules were expressed differently by antigen-
specific CD8+ T cells from infected and immunized mice. CD11c
was expressed only on a subset of specific CD8+ T cells of infected
mice but in all CD8+ T cells from immunized mice. CD122 was
expressed more strongly in specific CD8+ T cells from mice
immunized with the AdASP-2 vaccine; nevertheless, the expres-
sion was still low. On the other hand, PD1, CD43 (1B11), and
CD183 were upregulated only on the surface of specific CD8+ T
cells from immunized but not infected mice (Figure S4 A).
Consistent with the results described in A/Sn infected mice, we
found that the apoptotic receptor CD95 was upregulated only on
the surface of specific CD8+ T cells from infected but not
immunized mice. The kinetics of CD95 expression on the surface
of specific CD8+ T cells of infected mice revealed that the
maximum expression occurred at 14 to 28 days after infection.
Thereafter, a significant decline was observed. In contrast, the
expression of CD95 on specific CD8+ T cells from AdASP-2-
immunized mice did not change during the evaluation period in
comparison to that of naive CD8+ T cells (Figure S4 B).
MyD88 activation, IL-12 and IFN-type 1 are described as
important inflammatory mediators during T. cruzi infection in
mice [23]. Accordingly, we tested whether the upregulation of
CD95 on the surface of specific CD8+ T cells was dependent on
their expression. For that purpose, we used genetically deficient
(KO) mice that failed to express MyD88, p40 (IL-12/IL-23) or
IFN-1 receptor. As shown in Figure S5, specific CD8+ T cells from
infected MyD88, IL-12/IL-23 or IFN-1 receptor KO mice
upregulated CD95 on their surface at the same level as WT mice.
These results suggested that upregulation of CD95 was indepen-
dent of the expression of any of these molecules.
The fact that specific H2KK-TEWETGQI+ CD8+cells ex-
pressed higher amounts of the apoptotic receptor CD95 led us to
determine whether they could be indeed in a proapoptotic state.
Splenic H2KK-TEWETGQI+ CD8+cells were analyzed in infect-
ed, vaccinated or infected AdASP-2-immunized mice 19 days after
challenge/infection. We estimated their frequencies, expression of
CD95 and annexin V ligand and their in vivo proliferative capacity.
As earlier described, a significantly higher frequency of H2KK-
TEWETGQI+ CD8+ cells was detected in the spleen of infected-
AdSP-2 immunized mice (Gr. 4, Figure 5A). Also, the expression
of CD95 was higher on the surface of specific CD8+ from infected
mice (Gr. 2, Figure 5B, C and D). Most relevant was the fact that
we found that a higher frequency of H2KK-TEWETGQI+ CD95+
CD8+ cells from Gr. 2 (infected) mice stained positive for annexin
V (Gr. 2, Figure 5C). This frequency was significantly higher when
compared to that of cells from Gr. 4 (mean values,
58.05%66.38% and 17.29%66.42%, n = 3, respectively;
P,0.05).
To confirm that the lower frequency of specific CD8+ T cells
was not due to a diminished proliferative capacity of cells from
infected mice, we evaluated their in vivo proliferative capacity. We
found that a similar proportion of the H2KK-TEWETGQI+
CD8+ cells incorporated BrdU in vivo in infected or infected-
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Figure 4. Phenotypic characterization of specific CD8+ T cells of infected and/or AdASP-2 immunized A/Sn mice. A/Sn mice were
infected or immunized as described in the legend of Figure 3A. Splenic cells were collected nineteen days after infection/immunization. The
histograms show FACS analysis on CD8+ cells (Gr. 1) and H-2Kk-TEWETGQI+ CD8+ cells (Gr. 2, 3, and 4) and the indicated marker (blue). Control cells
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AdASP-2 vaccinated mice, indicating that the proliferative
capacity of these cells was not significantly different (Gr. 2 and
Gr. 4, Figure 5C). From these experiments, we concluded that in
the highly susceptible A/Sn mice, H2KK-TEWETGQI+ CD8+
cells were proliferating at a similar rate in infected or infected-
AdASP-2 immunized mice. Nevertheless, H2KK-TEWETGQI+
CD8+ cells from infected mice expressed higher levels of the
apoptotic receptor CD95 and the earlier apoptotic marker ligand
for annexin V.
We subsequently confirmed these observations using C57BL/6
mice. These mice were immunized and/or infected as described in
Figure S2 A. As shown in Figure S6 B, although a clear pattern of
upregulation of CD95 can be observed in cells from infected
animals (Gr. 2), no or limited regulation were observed in cells
from animals that were only immunized with AdASP-2 vaccine
(Gr. 3) or from infected-AdASP-2 immunized mice (Gr. 4),
respectively. Most important, we found that the frequency of
H2Kb-VNHRFTLV+ CD8+ cells from Gr. 2 (infected) mice that
stained for annexin V was higher than those of the other mouse
groups (Figure S6 B).
The observations that the specific CD8+ T cells showed a higher
CD95 expression and a pro-apoptotic phenotype in vivo strongly
suggest that these cells have a lower survival rate. Initially, we
tested their behavior upon CD95 engagement. Upon in vitro
exposure to aCD95, specific-CD8+ cells from infected mice (Gr. 2)
survived poorly. We estimated that 88.2% of them died
were from naive mice (red lines). Results of CD44, KLRG1 and CD183 staining are presented as MFI and frequencies of the CD44High, KLRG1High or
CD183High cells, respectively. On the other hand, results of CD27 and CD62L staining are presented as MFI and frequencies of the CD27Low or
CD62LLow cells. Representative analyses are shown from pools of cells from 3 mice. Stainings were performed 2 or more times with identical results.
doi:10.1371/journal.ppat.1002699.g004
Figure 5. Frequency, phenotypic characterization and proliferative capacity of specific CD8+ T cells. The protocol of the experiment was
as described in the legend of Figure 3A. A) Nineteen days after the immunization/challenge, we estimated the frequency of splenic H2Kk-TEWETGQI+
CD8+ cells. FACS charts are for a representative mouse (median) from 3 mice. Numbers represent frequencies of splenic cells. B) Splenic cells were
stained for CD8, H2Kk-TEWETGQI and CD95 prior to analysis by FACS (blue lines). Control cells were from naive mice (red lines). C) The histograms
show FACS analysis on CD8+ cells (Gr. 1) and H-2Kk-TEWETGQI+ CD8+ cells (Gr. 2, 3, and 4) stained for CD95 and annexin V ligand. Numbers represent
frequencies of CD8+ cells (Gr.1) or H2Kk-TEWETGQI CD8+ cells (Gr. 2, 3, and 4). D) Mice were treated with BrdU for 4 days prior to euthanasia and
splenic cells were stained for CD8, H-2Kk-TEWETGQI, CD95 and BrdU prior to FACS analysis. The histograms show analysis on CD8+ cells (Gr. 1) or
H2Kk-TEWETGQI+ CD8+ cells (Gr. 2, 3, and 4) stained for CD95 and incorporated BrdU. Numbers represent frequencies of CD8+ cells (Gr.1) or H2Kk-
TEWETGQI CD8+ cells (Gr. 2, 3, and 4). Mean numbers represents MFI for CD95 staining. Representative analyses (medians) are shown for 3 mice per
experiment. The experiment was performed two or more times with similar results.
doi:10.1371/journal.ppat.1002699.g005
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(Figure 6A). In contrast, under the same conditions, 73% of the
cells from AdASP-2-immunized mice (Gr. 3) survived. In the case
of AdASP-2-immunized and infected mice (Gr. 4), we observed
that a fraction of the cells (45%) survived the exposure to aCD95.
However, considering the high initial frequency of these cells, the
total of 0.54% of total splenic cells was still higher than the other
groups.
To test the in vitro proliferation capacity, we stimulated splenic
cells collected from infected C57BL/6 mice with the cognate
peptide VNHRFTLV. We observed that after 6 days in culture,
specific CD8+ cells from infected mice (Gr. 2) were no longer
detected (Figure 6B). In contrast, specific CD8+ cells from AdASP-
2-immunized mice, infected (Gr. 4) or not (Gr. 3) with T. cruzi,
were still alive. In the presence of the peptide, they also
proliferated. Based on that, we conclude that, in vitro, the ability
to survive to CD95 engagement or to survive for long periods of
time even in the presence of the antigen, was strikingly different
between specific CD8+ T cells from T. cruzi infected or AdASP-2
immunized mice. The possible reason why we found proliferating
cells in vivo, but not in vitro, is that in vivo, as the cells die, they were
being replenished by new ones which proliferate for few cycles. In
vitro, as they die, they disappear.
Because experimental T. cruzi infection can vary widely
according to the combination of mouse and parasite strain used,
we attempted to reproduce some of our results using a different
experimental model. For that purpose, we immunized BALB/c
mice with an adenoviral vaccine expressing the trans-sialidase
antigen of T. cruzi (AdTS), according to the protocol described in
Figure S7 A. AdTS contains the immunodominant H-2Kd-
restricted epitope, IYNVGQVSI [2,3,5,7]. Immunization with
AdTS vaccine significantly reduced the parasitemia caused by
parasites of the Brazil strain (Figure S7 B). On day 28 post
infection, we again observed a higher frequency of specific cells in
mice simultaneously immunized with AdTS vaccine when
compared to those in the other mouse groups. The frequency of
specific CD8+ cells as determined by staining with the multimer H-
2Kd-IYNVGQVSI was 3–4 times higher in infected AdTS-
immunized mice than in mice that had only been infected or
immunized (Figure S7 C). Estimates of frequencies of peptide-
specific CD8+ cells by ICS assays also detected 6.89- or 18.92-
times higher CD107a- and IFN-c- and/or TNF-a-positive cells in
infected AdTS-immunized mice than in infected or immunized
mice, respectively (Figure S7 D).
To extend the observations for CD95 expression by specific
CD8+ T cells, we compared the phenotypes of H2Kd-
IYNVGQVSI+ CD8+ cells from the different mouse groups. A
clear pattern of upregulated expression of CD95 was observed in
specific CD8+ T cells from infected animals (Gr. 2, Figure S8 B).
In contrast, cells collected from mice immunized with the AdTS
vaccine (Gr. 3) did not modulate CD95 expression. H2Kd-
IYNVGQVSI+ CD8+ cells from mice immunized with the AdTS
vaccine before challenge expressed significantly lower levels of
CD95 than those of specific CD8+ T cells from infected animals
(Gr. 2, Figure S8 B). This different pattern was not observed when
we estimated the expression of KLRG1 and CD95L on the surface
of these same cells (Figure S8 C and D, respectively). The
difference is also observed after different days of infection (Figure
S8 E). We concluded from these experiments that T. cruzi infection
with 2 distinct strains of the parasite leads to an upregulation of
CD95 expression on parasite-specific CD8+ T cells. On the other
hand, immunization with distinct adenoviral vaccines does not
modulate CD95 expression on transgene-specific CD8+ T cells.
Finally, priming with the adenoviral vaccines prior to or
simultaneously with the challenge partially prevents aberrant
CD95 expression on parasite-specific CD8+ T cells in these
different infection models.
Discussion
In the present study, we investigated the cellular and molecular
mechanisms that may account for the suboptimal immunity of
specific CD8+ T cells generated during infection with T. cruzi in
mice. Accordingly, our strategy was to compare the suboptimal
immune response elicited by parasite infection with the response
elicited by a highly effective adenoviral vaccine expressing the
parasite’s immunodominant epitopes. Our main hypothesis was
that CD8+ T cells induced by T. cruzi infection had one or more
Figure 6. In vitro survival capacity of specific CD8+ T cells from
infected and/or AdASP-2 immunized mice. A) A/Sn mice were
immunized i.m. with Adb-gal or AdASP-2 vaccine (26108 pfu/mouse).
On the same day, half of the mice were challenged s.c. with
trypomastigotes of the Y strain of T. cruzi (150 bloodstream parasites/
mouse). Twenty days after the immunization/challenge, splenic cells
were cultured in the presence of aCD95 (10 mg/mL) or Medium. After
24 h, we estimated the frequencies of splenic H2Kk-TEWETGQI+ CD8+
cells. Results are from pools of cells from four mice. The experiment was
performed twice with similar results. Mice were immunized i.m. with
26108 pfu of the recombinant adenovirus and challenged s.c. with 104
trypomastigotes of T. cruzi as described in the Figure S2 A. Twenty one
days after adenoviral immunization, splenic cells were immediately
stained with anti-CD8 and H2Kb-VNHRFTLV prior to FACS analysis (Day
0). Alternatively, they were labeled with CFSE and cultured in the
absence or presence of 10 mM VNHRFTLV (Day 6). After that period, the
cells were stained with anti-CD8 and H2Kb-VNHRFTLV prior to FACS
analyses. Results are from pools of cells from three mice. These mice
were also analyzed individually and the results were identical. The
numbers represent the frequency of CD8+ cells in each quadrant. The
asterisks and crosses denote significantly higher numbers of peptide-
specific cells than in the group of mice immunized with Adb-gal or all
other groups, respectively (P,0.05).
doi:10.1371/journal.ppat.1002699.g006
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properties not present in cells expanded by adenoviral vaccines,
and this caused a suboptimal immune response.
A detailed comparison of the specific CD8+ T cells elicited by
infection or vaccination revealed that, in general, the cells
overlapped in their functional or phenotypic characteristics.
Epitope-specific CD8+ T cells were highly cytotoxic in vivo and
secreted IFN-c, a cytokine that is critical for control of T. cruzi
multiplication [3,17]. Further, these cells mobilize CD107a to their
surface after in vitro stimulation with the cognate peptide, indicating
that a large proportion of these cells are prepared for granule
exocytosis. This observation is supported by cytotoxicity experi-
ments showing that the specific T cells are highly cytotoxic in vivo.
Analysis of the expression of IFN-c and TNF-a by ICS also revealed
that after experimental infection or immunization with AdASP-2
vaccine, the majority of specific T cells were a population of
multifunctional T cells that mobilized surface CD107a and
expressed both cytokines. Other cytokines evaluated, such as IL-2
or IL-10, were not detected by ICS (data not shown, [18]).
Similarly to the functional aspects described above, the surface
phenotype of the specific CD8+ T cells was characteristic of
Teffector cells. The fact that effector functions of CD8
+ T cells
elicited by T. cruzi infection overlap with those elicited by the
AdASP-2 vaccine emphasizes that these cell functions may be
important for control of the pathogen multiplication and, in the
case of the most mouse strains, the acute-phase pathology.
A clear difference we observed between the immune responses
elicited by T. cruzi infection or AdASP-2 vaccine was in the kinetics
of the immune response. The generation of cytotoxicity and IFN-
c-producing cells occurred faster in mice immunized with the
AdASP-2 vaccine than in those infected with T. cruzi a fact
previously described by us and others [2,3,4,24]. The precise
reasons for the delay in the immune response after T. cruzi
challenge are debatable and certainly may be important for the
parasite to establish a successful infection. In earlier studies, the
timing for the development of the T-cell immune response was
critically controlled by the parasite load [2,4,24]. Because parasites
contain antigen and, possibly, yet to be identified adjuvant
molecules, the effect of the parasite load could be associated with
either one individually, or both. Padilla et al. [24] proposed that
the delay was not due to the absence of parasite antigen but to the
absence of sufficient parasite TLR agonists considered as T. cruzi
adjuvant molecules. We question this interpretation because,
recently, we described that the development of the CD8+ T cell
immune response during experimental T. cruzi infection pro-
gressed well in genetically deficient mice that do not express TLR-
2, TLR-4, TLR-9, or even the adaptor molecule MyD88 [25].
Further, even when the host immune response was accelerated by
the addition of TLR agonists, no changes in the acute-phase
pathology were described [24]. Therefore, other intrinsic charac-
teristics of the CD8+ T cells may explain the difference in the
timing of specific CD8+ T-cell activation.
In accord with this possibility, an important observation from
our study was that epitope-specific CD8+ T cells expanded during
infection expressed higher levels of CD95 than naive CD8+ cells or
epitope-specific cells from mice immunized with adenoviral
vaccines. This phenomenon occurred in different mouse strains
(A/Sn, C57BL/6 and BALB/c) infected with 2 distinct parasite
isolates (Y and Brazil). This aspect is important because in many
cases there may be differences when using different parasites
isolates in terms of mechanism of immunity activated during
infection [26]. This aberrant pattern of upregulated expression
was the only one consistently observed when compared to any
other surface adhesion/homing/activation receptor that we
analyzed. In addition to the specific CD8+ T cells expressing
higher levels of CD95, CD95hi cells stained positively for annexin
V, a marker for apoptotic cells. Compatible with an increased
apoptosis rate, we found that specific CD8+ T cells accumulated
less in vivo. These smaller numbers cannot be explained by lower
proliferation rates. In vivo incorporation of BrdU indicated similar
proliferation rates of cells from infected and infected AdASP-2-
vaccinated mice.
CD95 functions during the immune response are multiple and
still the subject of intense studies [27–29]. The presence of low
levels of CD95L on the surface of antigen-presenting cells (APCs)
may serve as a co-stimulatory signal for naive CD95-expressing T
cells [30]. On the other hand, higher levels of the ligand provide a
negative signal for these same cells by blocking their activation
through the CD3 complex [30,31]. The presence of CD95L on
the surface of pathogen-infected APCs has been suggested as a
possible mechanism to downmodulate the immune response [31].
We could not find evidence of this theory as we could not detect
CD95L on the surface of dendritic cells infected with T. cruzi (J.
Ersching and MMR, unpublished results).
Because CD95 is an important initiator of the intrinsic pathway
of apoptosis in T lymphocytes, later it cooperates with Bim in
retraction of the T-cell immune response [32–34]. The observa-
tion that specific CD8+ T cells undergo modulation of CD95
expression after infection was described in specific CD8+ T cells
following mouse infection with LCMV or in individuals infected
with HIV. In the case of LCMV infection, lower levels of CD95
expression on specific CD8+ T cells located in the peripheral
organs is associated with an increased resistance to activation-
induced cell death in vitro [35]. In the case of human HIV
infection, higher expression of CD95 leads to increased suscep-
tibility to CD95/CD95L-mediated apoptosis and may compro-
mise the immune response of specific CD8+ T cells [36].
Upregulation of CD95 expression was also described in splenic
T cells during acute infection with certain T. cruzi strains [37].
Most relevant biologically was that in this model of infection, in vivo
injection of antibody to CD95L, which blocks the interaction with
CD95, reduced apoptosis, improved type-1 immune responses,
and reduced the infection severity as estimated by parasitemia
[37]. Similar treatment with anti-CD95L or anti-PD1 during
infection of the highly susceptible A/Sn mice with parasites of the
Y strain of T. cruzi did not reduce the parasitemia or the mortality,
indicating that these treatments alone cannot substitute for
immunization with AdASP-2 vaccine (AFA and MMR, unpub-
lished results). The reasons for the failure observed with the anti-
CD95L treatment are not clear. However the fact that CD95 is
expressed in a number of different cell types which play a diverse
role during the immune response may account for the difficulty to
block solely the interaction of CD95 expressed on the surface of
specific-CD8+ T cells.
The precise reason(s) why CD95 is differentially modulated after
infection with T. cruzi or adenoviral vaccination is unknown at
present. Herein, we tested whether 2 important mediators of
inflammation during T. cruzi experimental infection (MyD88, IL-
12 and IFN type I) could account for this pattern of CD95
expression on specific CD8+ T cells. Our results demonstrated that
during infection the CD95 upregulation process was independent
of the expression of each one of these mediators individually.
Because these molecules are involved directly or indirectly with
most cytokines that are largely produced during T. cruzi infection,
these results may indicate that the signal for CD95 up-regulation
may be given by direct interaction between APC, CD8 and CD4.
To date and to our knowledge, generally the cellular and
molecular mechanisms modulating CD95 expression on lympho-
cytes have been poorly explored. Cytokines IL-6 and type I IFN
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were described as factors that either downregulate or upregulate
CD95 expression, respectively [38,39]. The environment of T.
cruzi infection is relatively poor in IL-6 but rich in type 1 IFN [40–
42]. It is possible that this imbalance favors the expression of
CD95. On the other hand, the in vivo environment following
immunization with human adenovirus (including recombinant
type 5) is rich in type 1 IFN and IL-6. This balance may block the
upregulation of CD95 [43].
A very recent observation also correlated a defective CD8+ T cell-
mediated anti-tumor immune response with the aberrant expression
of CD95 and PD1 by these cells. This pattern of CD95 expression
by CD8+ T cells was reproduced by stimulating transgenic CD8+ T
cells in vitro with immature dendritic cells pulsed with the cognate
peptide [44]. Whether immature or T. cruzi-infected dendritic cells
also have the ability to upregulate the CD95 expression of CD8+ T
cells in vivo is an interesting possibility that should be evaluated.
Finally, cyclon, a newly identified cytokine-inducible protein
produced by T cells upon TCR activation, has been shown to
exert a key role in the process of CD95 expression [45]. Whether
cyclon expression following TCR activation plays a role in our
system also remains to be determined.
The fact that AdASP-2 vaccine fails to upregulate CD95 and
changes the program of CD8+ T cells expanded after an infectious
challenge is unexpected but may be desirable for an efficient
immune response. The lower levels of CD95 expressed would
render these cells resistant to parasite-induced apoptosis. In fact,
we observed that adenoviral-induced CD8+ T cells of multiple
specificities were not affected by ongoing T. cruzi infection (JRV
and MMR, unpublished observations). These observations disfa-
vor the hypothesis that cytokines generated during infection can
nonspecifically trigger upregulation of the CD95 molecule on
activated CD8+ T lymphocytes.
Based on our observations, we propose a model depicted in
Figure 7. The initial contact of specific CD8+ T cells with APC
loaded with T. cruzi antigen will lead to a molecular program
characterized by a higher expression of CD95 and a lower viability
(Gr. 2, T. cruzi infected mice). The low viability of specific CD8+ T
cells will preclude optimal immune response. Host pathology is
developed that may lead to death or chronic infection.
As oppose, initial contact with APC loaded with AdASP-2
antigens will lead to different molecular program of priming and
expansion of specific CD8+ T cells (Gr. 3, AdASP-2 immunized
mice). Upon a second contact, primed CD95Low specific CD8+ T
cells will proliferate intensively and display a significantly higher
viability (Gr. 4, AdASP-2 immunized and infected mice). This
accelerated proliferation coupled to a high viability would lean the
equilibrium towards an efficient host immune response and
parasite elimination.
The absence of an aberrant CD95 expression not only facilitates
the development of a protective immune response by slowing the
rate of apoptosis but it also reduces the formation of apoptotic
bodies. Apoptotic bodies are described as powerful immune
modulators during T. cruzi infection. Binding of apoptotic
lymphocytes to aVb3 expressed by macrophages leads to PGE2
and TGF-b production by macrophages, followed by the
induction of ornithine decarboxylase and the synthesis of
putrescine, which function as growth factors for intracellular
forms of T. cruzi [46–48].
The reduction of CD95 expression on the surface of specific
CD8+ T cells expanded following pathogen challenge may be
important not only in our infection model but also in vaccination
against other infectious diseases. As mentioned above, during
HIV/SIV infection, CD8+ T cells upregulate CD95 expression
[35,49,50]. Blocking the interaction of CD95/CD95L in vivo by
treatment with anti-CD95L antibody preserved memory lympho-
cytes and cell-mediated immunity in SIV-infected primates [51].
Further, by down-modulating CD95 expression, adenoviral
vaccines may reduce the formation of apoptotic bodies. As in
the case of T. cruzi infection, these apoptotic bodies may fuel viral
growth [52].
The possibility that vaccination may selectively alter specific
CD8+ T cell phenotype and change the expression of surface
receptors is only now beginning to be explored. Recently, it was
described in humans that during immune responses to melanoma
tumors, antigen-specific CD8+ T cells maintained high expression
levels of the inhibitory receptor B and T lymphocyte attenuator
(BTLA). Multiple vaccination doses with peptides representing
CD8 epitopes in the presence, but not in the absence, of the TLR-
9 agonist CpG ODN led to progressive downregulation of BTLA
in vivo, increased resistance to BTLA-mediated inhibition, and
improved T cell function [53]. This study provides important
evidence that vaccination can modify antigen-specific CD8+ T
cells, thereby qualitatively improving their function. Further, by
using this same adjuvant (a TLR-9 agonist), Muraoka et al. [44]
modified a defective CD8+ T cell-mediated anti-tumor immune
response to a productive one by counteracting the aberrant
expression of CD95 and PD1 on CD8+ T cells.
We consider that these results may facilitate understanding of
the host–parasite relationship and present some new interpreta-
tions of the functions of T-cell vaccines. Recombinant replication-
defective human and simian adenoviral vectors have proven
successful against a variety of experimental infections, such as SIV,
TB, malaria, toxoplasmosis, Marburg virus infection, and Ebola
[54–69]. Nonetheless, the precise reason for their success is still
unknown. By understanding the potential of these vectors to elicit
an immune response and simultaneously to modulate acquired
immune responses in the host, it might be possible to design
simpler and more effective vaccine formulations.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Brazilian National Council of Animal
Experimentation (http://www.cobea.org.br/). The protocol was
approved by the Committee on the Ethics of Animal Experiments
of the Institutional Animal Care and Use Committee at the
Federal University of Sao Paulo (Id # CEP 0426/09).
Mice and parasites
Female 5- to 8-week-old A/Sn, C57BL/6, BALB/c, p40-
deficient (IL-12/IL-23 KO, [70]), MyD88- (MyD88 KO, [71])
and Interferon-I receptor (IFN-I rec KO, [72])-deficient mice were
purchased from the University of Sa˜o Paulo. Parasites of the Y or
Brazil strain of T. cruzi were used in this study [2,3]. Bloodstream
trypomastigotes were obtained from mice infected 7 to 28 days
earlier with parasites of the Y or Brazil strain, respectively. After
estimating the parasite concentration, the blood was diluted in
PBS to the desired concentration. Each mouse was inoculated with
150 trypomastigotes (A/Sn), 104 trypomastigotes (C57Bl/6), or
103 trypomastigotes (BALB/c) diluted in 0.2 mL PBS and
administrated subcutaneously (s.c.) in the base of the tail.
Monitoring the presence of persisting bloodstream
trypomastigotes
Parasite development was monitored by counting the number of
bloodstream trypomastigotes in 5 mL of fresh blood collected from
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the tail vein. Mouse survival was recorded daily. Twenty four
months after challenge, the parasitemia was undetectable. To
evaluate whether there was still a very small amount of viable
circulating parasites, we collected 0.5 mL of the blood and
transferred i.p. to naı¨ve highly susceptible A/Sn mice.
Peptide synthesis
Synthetic peptides were purchased from Genscript (Piscataway,
New Jersey). Peptide purity was higher than 90%. Peptide
identities were confirmed by a Q-TOF Micro equipped with an
electrospray ionization source (Micromass, UK). The immunodo-
Figure 7. Proposedmodel for the differences in activation of specific CD8+ T cells. The initial contact of specific CD8+ T cells with APC loaded
with T. cruzi antigen leads to a molecular program characterized by a higher expression of CD95 and a lower viability (Gr. 2). Due to the low viability of
theses specific CD8+ T cells, optimal immune response are not generated and host pathology is developed leading to death or chronic infection. In
contrast, contact of APC loaded with AdASP-2 antigens leads to a molecular program of priming and expansion of specific CD8+ T cells (Gr. 3). Upon a
second contact with T. cruzi, primed CD95Low specific CD8+ T cells proliferate intensively and display a significantly higher viability (Gr. 4). This
accelerated proliferation of highly viable CD8+ T cells lean the equilibrium towards an efficient host immune response (cure) and parasite elimination.
doi:10.1371/journal.ppat.1002699.g007
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minant epitopes of ASP-2 and TS were represented by AA
VNHRFTLV and AA IYNVGQVSI, respectively. The sub-
dominant epitope TsKb-20 was represented by AA ANYKFTLV
(purity 99.7%).
The pentamer H2Kb-VNHRFTLV was purchased from
ProImmune Inc. (Oxford, UK). The dextramers H2Kk-TE-
WETGQI and H2Kd-IYNVGQVSI were purchased from Im-
mudex (Copenhagen, Denmark).
Adenoviruses used for immunization
Recombinant human type 5 replication-defective adenoviruses
expressing T. cruzi Amastigote Surface Protein-2 (AdASP-2) or TS
(AdTS) were generated, characterized, grown, and purified as
previously described [17]. Mice were inoculated intramuscularly
(i.m.) in each tibialis anterior muscle with 50 mL of viral suspension
containing the indicated plaque forming units (pfu). In some
experiments mice were inoculated by the s.c. route at the base of
the tail. Immunological assays were performed at the indicated
days after viral inoculation.
Immunological interventions and readout assays
In vivo depletion of CD8+ T cells was performed by treating
vaccinated A/Sn mice with 53.6.7 MAb. On days 26, 24, and
22 and before challenge with trypomastigotes, mice were injected
i.p. with a dose of 0.5 mg of anti-CD8 or control rat IgG. Seven
days after challenge, each mouse received one more dose of
0.5 mg of anti-CD8 or rat IgG. The efficacy of depletion of CD8+
spleen cells before challenge was more than 96% in anti-CD8-
treated mice compared to that of the rat IgG-treated ones (data
not shown).
For the surface mobilization (expression) of CD107a and the
intracellular expression of cytokines (IFN-c and TNF-a, ICS),
splenocytes collected from A/Sn, C57BL/6 or BALB/c mice were
treated with ACK buffer (NH4Cl, 0.15 M; KHCO3, 10 mM; Na2-
EDTA 0.1 mM; pH = 7.4) for lysing the erythrocytes. Surface
mobilization of CD107a and ICS were evaluated after in vitro
culture of splenocytes in the presence or absence of the antigenic
stimulus. Cells were washed 3 times in plain RPMI and re-
suspended in cell culture medium consisting of RPMI 1640
medium, pH 7.4, supplemented with 10 mM Hepes, 0.2% sodium
bicarbonate, 59 mg/L of penicillin, 133 mg/L of streptomycin,
and 10% Hyclone fetal bovine sera (Hyclone, Logan, Utah). The
viability of the cells was evaluated using 0.2% trypan blue
exclusion dye to discriminate between live and dead cells. Cell
concentration was adjusted to 56106 cells/mL in cell culture
medium containing anti-CD28 (2 mg/mL), brefeldin A (10 mg/
mL), monensin (5 mg/mL), and FITC-labeled anti-CD107a
(Clone 1D4B, 2 mg/mL; BD Pharmingen). In half of the cultures,
a final concentration of 10 mM of the VNHRFTLV, TEWETGQI
or IYNVGQVSI peptide were added. The cells were cultivated in
flat-bottom 96-well plates (Corning) in a final volume of 200 mL in
duplicate, at 37uC in a humid environment containing 5% CO2.
After 12-h incubation, cells were stained for surface markers with
PerCP- and PE-labeled anti-CD8, on ice for 20 min. To detect
IFN-c and TNF-a by intracellular staining, cells were then washed
twice in buffer containing PBS, 0.5% BSA, and 2 mM EDTA,
fixed in 4% PBS-paraformaldehyde solution for 10 minutes, and
permeabilized for 15 minutes in a PBS, 0.1% BSA, and 0.1%
saponin solution. After being washed twice, cells were stained for
intracellular markers using APC- and PE-labeled anti-IFN-c
(Clone XMG1.2) and PE-labeled anti-TNF-a (clone MP6-
XT22), for 20 minutes on ice. Finally, cells were washed twice
and fixed in 1% PBS-paraformaldehyde. At least 300,000 cells
were acquired on a BD FacsCanto flow cytometer and then
analyzed with FlowJo.
For the in vivo cytotoxicity assays, splenocytes collected from
naive BALB/c or C57BL/6 mice were treated with ACK buffer
(NH4Cl, 0.15 M; KHCO3, 10 mM; Na2-EDTA 0.1 mM;
pH = 7.4) for lysing the erythrocytes. These cells were divided
into 2 populations and labeled with the fluorogenic dye
carboxyfluorescein diacetate succinimidyl diester (CFSE; Molec-
ular Probes, Eugene, Oregon, USA) at a final concentration of
5 mM (CFSEhigh) or 0.5 mM (CFSElow). CFSEhigh cells were coated
for 40 min at 37uC with 1 mM of H-2Kb ASP-2 peptide
VNHRFTLV. CFSElow cells remained uncoated. Subsequently,
CFSEhigh cells were washed and mixed with equal numbers of
CFSElow cells, and 30 to 40610
6 total cells per mouse were
injected intravenously (i.v.). Recipient animals were mice previ-
ously immunized with adenoviruses. Spleen cells of recipient mice
were collected 4 h or 20 h after transfer as indicated on the legend
of the figures, fixed with 1.0% paraformaldehyde and analyzed by
flow cytometry by using a FacsCanto flow cytometer (BD,
Mountain View, CA). The percentage of specific lysis was
determined using the following formula:
1{ %CFSEhigh immunized

%CFSElow immunized
 
%CFSEhigh naive

%CFSElow naive
 
|100%:
For flow cytometry analyses, we used mouse splenocytes treated
with ACK buffer. Single-cell suspensions were washed in PBS,
stained for 10 min at RT with biotinylated MHC I multimer H-
2Kb-VNHRFTLV, and stained for 20 min at 4uC with avidin-
APC- and PerCP-labeled anti-CD8 antibodies (both from BD
Pharmingen). Alternatively, splenic cells were stained for 10 min
at RT with H2Kk-TEWETGQI and H2Kd-IYNVGQVSI dex-
tramers (both APC-labeled) and PerCP-labeled anti-CD8 anti-
body. For the analyses of other cell-surface markers, single-cell
suspensions from spleens of mice were stained with multimers and
PerCP-labeled anti-CD8 antibody as described above. Then,
FITC-labeled anti-CD11a (clone 2D7), anti-CD11c (clone HL3),
anti-CD25 (clone 7D4), anti-CD31 (clone MEC13.3), anti-CD43
(clone S7), anti-CD44 (clone IM7), anti-CD49d (clone R-12), anti-
CD62L (clone MEL-14), anti-CD69 (clone H1.2F3), anti-CD95
(clone Jo2), anti-CD122 (clone TM-b1), anti-CD127(clone SB/
199), anti-CD95L (MFL3), anti-BTLA (8F4), anti-PD1 (J43), anti-
CTLA4 (UC10-4B9), and anti-CCR-7 (4B12) (all from BD
Pharmingen). Anti-CD27 (clone LG.7F9) and anti-KLRG-1 (clone
MAFA) were purchased from eBioscience (San Diego, CA). Anti-
CD43 (1B11) and anti-CD183 (CXCR3-173) were purchased
from Biolegend (San Diego, CA). Annexin-V-PE staining was
performed with a kit according to the manufacturer’s instructions
(BD Pharmingen). For detection of BrdU, mice were injected i.p.
with 2 mg of BrdU (Sigma) for 4 days before euthanasia. The cells
were treated according to the manufacturer’s kit instructions and
stained with anti-BrdU-APC (BD Pharmingen). At least 100,000
cells were acquired on a BD FacsCanto flow cytometer and then
analyzed with FlowJo (Tree Star, Ashland, OR).
In vitro survival assay were performed by culturing the A/Sn
splenic cells collected 20 days after inoculation of parasites or
adenoviruses for 24 h in the presence or absence of anti-CD95
(clone Jo2, 10 mg/mL). Cell culture medium contained murine
recombinant IL-2 (Sigma, 0.1 U/mL) and 106 cells/0.2 mL. After
this period, cells were stained with anti-CD8 and dexamers H-
2Kk-TEWETGQI before FACS analyses.
Alternatively, C57BL/6 splenic cells were collected from mice
at the indicated days post immunization and/or challenge. These
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cells were labeled with 10 mM of CFSE as described above and
106 cells/0.2 mL maintained for 6 days in culture medium
containing or not the peptide VNHRFTLV (10 mM). After this
period, cells were stained with anti-CD8 and pentarmers H-2Kb-
VNHRFTLV before FACS analyses.
Statistical analysis
The values of parasitemia of each individual mouse were log
transformed before being compared by one-way ANOVA
followed by Tukey Honesty Significance Difference tests, available
at the following site: http://faculty.vassar.edu/lowry/VassarStats.
html. The logrank test was used to compare mouse survival rates
after challenge with T. cruzi. The differences were considered
significant when the P value was ,0.05.
Supporting Information
Figure S1 Parasitemia and kinetics of specific CD8+ T
cell-mediated immune responses during infection or
vaccination. A) Parasitemia of C57BL/6 mice infected s.c. with
104 bloodstream trypomastigotes of T. cruzi B) Mice were infected
s.c. or not with T. cruzi trypomastigotes as described above. In
parallel, mice were immunized i.m. with AdASP-2 vaccine
(26108 pfu/mouse). At the indicated days, the in vivo cytotoxic
activity against target cells coated with peptide VNHRFTLV was
determined as described in the Methods Section. The results
represent the mean 6 SD values for 4 mice per group. The results
are representative of 3 independent experiments. C–F) C57BL/6
mice were infected or immunized as described above. Control
mice were either naive mice or mice immunized with Adb-gal
(26108 pfu/mouse). At the indicated days after infection or
immunization, these mice had their splenic cells cultured in the
presence of anti-CD107a and anti-CD28, with or without the
peptide VNHRFTLV. After 12 h, cells were stained for CD8,
IFN-c, and TNF-a. Frequencies were estimated for CD8+ cells
expressing the indicated molecules after stimulation in vitro with
peptide VNHRFTLV. The results are expressed as the mean 6
SD values for 4 mice per group. The values of cultures stimulated
with peptide VNHRFTLV were always subtracted from those of
cultures with medium alone. Pie charts show the fraction of
peptide-specific cells expressing the indicated molecules. The
results are expressed as the mean values for 4 mice per group. The
asterisks and crosses denote significantly higher numbers of
peptide-specific cells than in the group of mice immunized with
Adb-gal or all other groups, respectively (P,0.05).
(PPT)
Figure S2 Specific CD8+ T cell-mediated immune
responses of infected, immunized or infected AdASP-2
immunized C57BL/6 mice. A) C57BL/6 mice were immu-
nized i.m. with 26108 pfu/mouse of the indicated recombinant
adenovirus. Seven days later, half of the mice were challenged s.c.
with 104 trypomastigotes of the Y strain of T. cruzi. B) Twenty one,
days after immunization with recombinant adenovirus, the splenic
cells of these mice were cultured in the presence of anti-CD107a
and anti-CD28, with or without the peptide VNHRFTLV. After
12 h, cells were stained with anti-CD8, anti-IFN-c, and anti-TNF-
a. The results are expressed as the total frequency of CD8+ cells
stained for any of the indicated molecules (mean6 SD values for 4
mice per group). The values of cultures stimulated with peptide
VNHRFTLV were always subtracted from those of cultures with
medium alone. C) The same as described above except that the
results are expressed as the frequencies of the indicated
subpopulation of CD8+ cells stained for CD107a, IFN-c, and
TNF-a (mean 6 SD values for 4 mice per group). D) Pie charts
show the fraction of peptide-specific cells expressing the indicated
molecules. The results are expressed as the mean values for 4 mice
per group. The asterisks and crosses denote significantly higher
numbers of peptide-specific cells than in the group of mice
immunized with Adb-gal or all other groups, respectively
(P,0.05).
(PPT)
Figure S3 Epitope-specific CD8+ T cell-mediated im-
mune responses of infected and/or immunized immu-
nized C57BL/6 mice. A) C57BL/6 mice were immunized i.m.
with 26108 pfu/mouse of the indicated recombinant adenovirus.
Seven days later, half of the mice were challenged s.c. with 104
trypomastigotes of the Y strain of T. cruzi. B) Twenty seven days
after immunization with recombinant adenovirus, we estimated
the frequency (%) of splenic H2Kb-VNHRFTLV+ CD8+ cells.
The results represent a pool of cells from 4 mice per group. C)
Twenty seven days after immunization with recombinant
adenovirus, the splenic cells of these mice were cultured in the
presence of anti-CD28, with or without the peptide VNHRFTLV
or TsKb-20. After 12 h, cells were stained with anti-CD8, anti-
IFN-c, and anti-TNF-a. The results are expressed as the total
frequency (%) of CD8+ cells stained for any of the indicated
molecules (mean 6 SD values for 4 mice per group). The asterisks
denote significantly higher numbers of peptide-specific cells in Gr.
4 when compared to the same sample of Gr. 2 (P,0.05).
(PPT)
Figure S4 Phenotypic characterization of specific CD8+
T cells induced by T. cruzi infection or AdASP-2
immunization. C57BL/6 mice were infected or immunized as
described in the legend of Figure 2. Control mice were naive mice.
A) Twenty-eight or 14 days after infection or immunization,
respectively, these mice had their splenic cells stained with anti-
CD8, H2Kb-VNHRFTLV, and the indicated marker-specific
antibody labeled prior to analysis by FACS. The histograms show
the expression of the markers on H2Kb-VNHRFTLV+ CD8+ T
cells (green lines) or control naive CD8+ spleen cells (red lines).
Representative analyses are shown from pools of cells from 3 mice.
Experiments were performed 3 or more times with identical
results. B) At the indicated days after infection or immunization,
splenic cells were stained with anti-CD8, H2Kb-VNHRFTLV,
and the indicated marker-specific antibody labeled prior to
analysis by FACS. Numbers in red or green represent mean
fluorescence intensity.
(PPT)
Figure S5 Phenotypic characterization of epitope-spe-
cific CD8+ T cells induced by infection of genetically
deficient C57BL/6 mice with Y strain of T. cruzi. C57BL/
6 mice (WT, MyD88, IL-12/IL-23 KO or IFN-1 receptor KO)
were infected s.c. with 104 blood forms of T. cruzi Y strain. Control
mice were naive mice of the different strains. Fourteen days after
infection, the splenic cells of these mice were stained with anti-
CD8, H2Kb-VNHRFTLV, anti-CD95 and anti-CD44 prior to
analysis by FACS. The histograms show the expression of the
markers: a) H2Kb-VNHRFTLV and CD8 on splenic cells form
infected or control naive CD8+ spleen cells; b) CD95 and CD44
on H2Kb-VNHRFTLV + (blue lines) or naive CD8+ cells (red
lines). Numbers in red or blue represent mean fluorescence
intensity. Analyses are shown for a representative from 3 mice.
(PPT)
Figure S6 Phenotypic characterization of specific CD8+
T cells of infected and/or AdASP-2 immunized C57BL/6
mice. A) Mice were immunized i.m. with 26108 pfu of the
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indicated recombinant adenovirus and challenged s.c. with 104
trypomastigotes of T. cruzi. B) Control cells were CD8+ T cells
from naive mice (red lines). Splenic cells were stained with anti-
CD8, H2Kb-VNHRFTLV, anti-CD95 and annexin V prior to
FACS analysis (blue lines). The histograms show FACS analysis on
CD8+ cells (Gr. 1) or H2Kb-VNHRFTLV+ CD8+ cells (Gr. 2, 3,
and 4) stained for CD95 or incorporated BrdU. Representative
analyses are shown from pools of cells of 3 mice per experiment.
Analyses of each individual mouse provided the same result. The
results for the annexin V ligand are expressed as the percentage of
positive cells. The experiment was performed 3 times with similar
results.
(PPT)
Figure S7 Specific CD8+ T cell-mediated immune
responses of infected and/or AdTS immunized BALB/c
mice. A) BALB/c mice were immunized i.m. with of Adb-gal or
AdTS vaccine (26108 pfu/mouse). One week later, half of the
mice were challenged s.c. with trypomastigotes of the Brazil strain
of T. cruzi (103 bloodstream parasites/mouse). B) Parasitemia (per
mL) was estimated at the indicated days following infection of mice
that had been immunized with Adb-gal (Gr. 2) or AdTS vaccine
(Gr. 4). The values of parasitemia were significantly lower in mice
from Gr. 4 (P,0.05, n = 4). C) Twenty eight days after challenge
(35 days after adenovirus immunization), we estimated the
frequency of splenic H2Kd-IYNVGQVSI+ CD8+ cells. The results
are presented in terms of each mouse (dots) and medians (bars). D)
On that day, the splenic cells were cultured in the presence of anti-
CD107a and anti-CD28, with or without the peptide
IYNVGQVSI. After 12 h, cells were stained for CD8, IFN-c,
and TNF-a. The results are presented as mean 6 SD frequencies
of splenic CD8+ cells of 4 mice. The values of cultures stimulated
with peptide IYNVGQVSI were subtracted from those of cultures
with medium alone. The asterisks and crosses denote significantly
higher numbers of peptide-specific cells than in the group of mice
immunized with Adb-gal or all other groups, respectively
(P,0.05). E) Pie charts show the fraction of peptide-specific cells
expressing the indicated molecules. The results are expressed as
the mean values for 4 mice per group. The results are
representative of 2 independent experiments. The asterisks and
crosses denote significantly higher numbers of peptide-specific cells
than in the group of mice immunized with Adb-gal or all other
groups, respectively (P,0.05).
(PPT)
Figure S8 Phenotypic characterization of specific CD8+
T cells of infected and/or AdTS immunized BALB/c
mice. A) Thirty five days after adenovirus immunization, we
estimated the frequencies of H2Kd- IYNVGQVSI+ CD8+ cells.
Because some of these mice were challenged 7 days after
immunization, this date represents 28 days after challenge with
parasites (Gr. 2 and Gr. 4). FACS charters are from a
representative mouse (median) from 3 mice. Numbers represent
percentage of splenic cells. B to D) Splenic cells were stained for
CD8, H2Kd- IYNVGQVSI, CD95, KLRG1, and CD95L prior to
analysis by FACS. The histograms show the expression of the
markers on H2Kd- IYNVGQVSI+ CD8+ cells (blue lines) or
control naive CD8+ spleen cells (red lines). Numbers in red or blue
represent mean fluorescence intensity. E) Kinetics of CD95
expression on H2Kd- IYNVGQVSI+ CD8+ cells (blue lines) at
different days after inoculation of the parasites. Control cells were
from naive mice (red lines). Representative samples (median) are
shown from 3 mice per experiment.
(PPT)
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